PUMP MMT-1884L MM780G BLE 3.0 mg/ml
Received Jul 31, 2026 · Event occurred Jul 13, 2026
Report 2032227-2026-216239 · MDR key 50096181
Device
Generic name
Interoperable Automated Glycemic Controller
Manufacturer
Medtronic Puerto Rico Operations Co.Model number
MMT-1884LCatalog number
MMT-1884L
Lot number
NG3421625H
Product problems
- Adverse Event Without Identified Device or Use Problem
Patient
45 YR · Female
- Dehydration
- Diarrhea
- Headache
- Hyperglycemia
- Pain
- Vomiting
- Malaise
- Elevated ketones/Diabetic Ketoacidosis
- Cramp(s) /Muscle Spasm(s)
Narrative
Description of Event or Problem
It was reported to Minimed that the customer experienced Hyperglycemia and elevated ketones/diabetic ketoacidosis. The customer reported blood glucose value of 420 mg/dL at the time of event. The customer reported symptoms like Feeling sick/unwell, Headache, Extremity pain/cramps, Increased thirst, Diarrhea, Vomiting at the time of hospitalization event. The customer was hospitalized and then treated in hospital with Intravenous Insulin infusion for hyperglycemia and diabetic ketoacidosis events. Customer reported discrepancy between sensor glucose and blood glucose values. The event involved product(s) UNOMEDICAL,UNK_RESERVOIR,MMT-1884L,UNK_ADCSENSOR. Troubleshooting was performed and the customer was using the insulin pump within 48 hours of the reported event. The Auto mode feature was used at the time of the event. No further patient complications were reported. No product return is required for UNOMEDICAL,UNK_RESERVOIR,MMT-1884L,UNK_ADCSENSOR.
Additional Manufacturer Narrative
This MDR related to the Puerto Rico manufacturing site has been assigned a MedWatch number from the Medtronic MiniMed Northridge site, per Variance 5. Currently it is unknown whether or not the device may have caused or contributed to the event as no product has been returned. No conclusion can be drawn at this time. We therefore consider this report complete to the best of our knowledge. Medtronic submits this report to comply with FDA regulations 21 CFR Parts 4 and 803. Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report. This report does not constitute an admission or a conclusion by FDA, Medtronic, or its employees that the device, Medtronic, or its employees caused or contributed to the event described in the report. Any required fields that are unpopulated are blank because the information is currently unknown or unavailable. Medtronic will submit a supplemental report if additional relevant information becomes known.